Determinants of the response of human blood vessels to nitric oxide donors in vivo

Journal of Pharmacology and Experimental Therapeutics

Volumn 289, Issue 3, 1999, Pages 1662-1668

  Barba, Gianvincenzo ^a   Mullen, Michael J ^b   Donald, Anne ^b   Macallister, Raymond J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

8 BROMO CYCLIC GMP; DIPYRIDAMOLE; GLYCERYL TRINITRATE; LINSIDOMINE; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM;

ARTICLE; BLOOD VESSEL REACTIVITY; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; FOREARM; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; RADIAL ARTERY; SECOND MESSENGER; VASCULAR RESISTANCE; VASODILATATION;

ADULT; BRADYKININ; CYCLIC GMP; DIPYRIDAMOLE; FOREARM; HAND; HUMANS; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE DONORS; NITROGLYCERIN; NITROPRUSSIDE; OMEGA-N-METHYLARGININE; RADIAL ARTERY; VASCULAR RESISTANCE; VASODILATION; VEINS;

EID: 0032990327     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Beavo JA (1995) Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol Rev 75:725-748.
2. Calver A, Collier J and Vallance P (1993) Nitric oxide and cardiovascular control. Exp Physiol 78:303-326.
3. Collier J, Lorge RE and Robinson BF (1976) Comparison of effects of tolmesoxide (RX71107), diazoxide, hydrallazine, prazosin, glyceryltrinitrate and sodium nitroprusside on forearm arteries and dorsal hand veins in man. Br J Clin Pharmacol 5:35-44.
4. Cooke JP and Dzau VJ (1997) Derangements of the nitric oxide synthase pathway, L-arginine and cardiovascular diseases. Circulation 96:379-382.
5. Fillipov G, Bloch DB and Bloch KB (1997) Nitric oxide decreases stability of mRNAs encoding soluble guanylate cyclase subunits in rat pulmonary artery smooth muscle cells. J Clin Invest 100:942-948.
6. Fullerton DA, Jaggers J, Piedalue F, Grover FL and McIntyre RC (1997) Effective control of refractory pulmonary hypertension after cardiac operations. J Thorac Cardiovasc Surg 113:363-370.
7. Hobbs AJ and Ignarro LJ (1996) The nitric oxide-cyclic GMP signal transduction system. Methods Enzymol 269:134-148.
8. Holzmann A, Bloch KD, Sanchez LS, Fillipov G and Zapol WA (1996) Hyporesponsiveness to inhaled nitric oxide in isolated perfused lungs from endotoxin-challenged rats. Am J Physiol 271:L981-L986.
9. Jonnides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C and Lüscher TF (1995) Nitric oxide is responsible for flow-dependent dilation of human peripheral conduit arteries in vivo. Circulation 91:1314-1319.
10. Lieberman EH, Gerhard MD, Uehata A, Selwyn AP, Ganz P, Yeung AC and Creager MA (1996) Flow-induced vasodilatation of the human brachial artery is impaired in patients <40 years of age with coronary artery disease. Am J Cardiol 78:1210-1214.
11. MacAllister RJ, Calver AL, Collier J, Edwards CMB, Herreros B, Nussey SS and Vallance P (1995a) Vascular and hormonal response to arginine: Provision of substrate for nitric oxide or non-specific effect? Clin Sci 89:183-190.
12. MacAllister RJ, Calver AL, Riezebos J, Collier J and Vallance P (1995b) Relative potency and arteriovenous selectivity of nitrovasodilators on human blood vessels: Implications for the targeting of nitric oxide delivery. J Pharmacol Exp Ther 273:154-160.
13. Moncada S, Rees DD, Schulz R and Palmer RMJ (1991) Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo. Proc Natl Acad Sci USA 88:2166-2170.
14. Mullen MJ, Thorne SA, Deanfield JE and Jonea CJ (1997) Non-invasive assessment of endothelial function. Heart 77:297-298.
15. G- monomethyl-arginine attenuates the vasodilator action of bradykinin in the human forearm. Br J Clin Pharmacol 38:311-315.
16. Panza JA, Casino PE, Badar DM and Quyyumi AA (1993) Effect of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension. Circulation 87:1475-1481.
17. Papapetropoulos A, Abou-Mohamed G, Marczin N, Murad F, Caldwell RW and Catravas JD (1996a) Downregulation of nitrovasodilator-induced cyclic GMP accumulation in cells exposed to endotoxin or interleukin-1β. Br J Pharmacol 118: 1359-1366.
18. Papapetropoulos A, Go CY, Murad F and Catravas JD (1996b) Mechanisms of tolerance to sodium nitroprusside in rat cultured aortic smooth muscle cells. Br J Pharmacol 117:147-155.
19. Soff GA, Cornwell TL, Cundiff DL, Gately S and Lincoln T (1997) Smooth muscle cell expression of type 1 cyclic GMP-dependent protein kinase is suppressed by continuous exposure to nitrovasodilators, theophylline, cyclic GMP and cyclic AMP. J Clin Invest 100:2580-2587.
20. Stamler JS, Loh E, Roddy MA, Currie KE and Creager MA (1994) Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 89:2035-2040.
21. Vaandrager AB and de Jonge HR (1996) Signalling by cGMP-dependent protein kinases. Mol Cell Biochem 157:23-30.
22. Vallance P, Collier J and Moncada S (1989a) Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 2:997-1000.
23. Vallance P, Collier J and Moncada S (1989b) Nitric oxide synthesized from L-arginine mediates endothelium-dependent dilatation in human veins in vivo. Cardiovasc Res 23:1053-1057.
24. Wennmalm Å, Benthin G and Petersson AS (1992) Dependence on the metabolism of nitric oxide (NO) in healthy human whole blood on the oxygenation of its red cell haemoglobin. Br J Pharmacol 106:507-508.
25. Whitney RJ (1953) The measurement of volume changes in human limbs. J Physiol 121:1-27.
26. Ziegler JW, Ivy DD, Fox JJ, Kinsella JP, Clarke WR and Abman SH (1995) Dipyridamole, a cGMP phosphodiesterase inhibitor, causes pulmonary vasodilation in the ovine fetus. Am J Physiol 269:H473-H479.